Search for: "REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC. "
Results 1 - 14
of 14
Sorted by Relevance
|
Sort by Date
17 Mar 2025, 9:49 pm
Cir. 2025)Regeneron Pharmaceuticals, Inc. v. [read post]
12 Mar 2025, 9:20 pm
Cir. 2025)Regeneron Pharmaceuticals, Inc. v. [read post]
17 Feb 2025, 9:07 pm
At trial, each case also included Defendants Mylan Pharmaceuticals Inc., Amgen USA, Inc., Biocon Biologics Inc., Celltrion, Inc., and Amgen Inc., as well as the two Defendants-Appellants. [read post]
6 Apr 2025, 8:54 pm
Mylan Pharmaceuticals Inc. [read post]
30 Jan 2025, 11:15 am
Court of Appeals for the Federal Circuit issued a precedential ruling in Regeneron Pharmaceuticals, Inc. v. [read post]
30 Jan 2025, 11:15 am
Court of Appeals for the Federal Circuit issued a precedential ruling in Regeneron Pharmaceuticals, Inc. v. [read post]
8 May 2025, 8:39 am
Cir. 2025)Regeneron Pharmaceuticals, Inc. v. [read post]
25 Mar 2025, 9:28 pm
Cir. 2025)Regeneron Pharmaceuticals, Inc. v. [read post]
24 Nov 2010, 12:37 am
General Global pharmaceutical linkage regulations: A consortium framework (IP Osgoode) Pfizer rolling out generics to grab off-patent market (GenericsWeb) Australia: Too little too late: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) and the judicial discretion to amend a patent (IP Whiteboard) Brazil: You lost your chance! [read post]
6 Nov 2015, 6:58 am
Therefore, it was not obvious to test pregabalin – it might be obvious to test gabapentin, but even here the judge considered that the skilled team would have little expectation of success.InsufficiencyAccording to the caselaw relating to sufficiency developed in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd [2011] EWHC 1699 (Pat) at [458]-[484] and summarised in Sandvik Intellectual Property AB v Kennametal UK Ltd [2011] EWHC 3311 (Pat) at… [read post]
1 Dec 2010, 12:15 am
Abraxis Bioscience, Inc. v. [read post]
29 May 2024, 11:27 am
Regeneron Pharmaceuticals, Inc. v. [read post]
3 Oct 2018, 8:51 am
Regeneron Pharmaceutical v. [read post]
9 Nov 2015, 7:39 am
Merck Sharp & Dohme v Ono Pharmaceutical [2015] EWHC 2973 (Pat), decided on 22 October by Mr Justice Birss in the Patents Court, England and Wales, is a decidedly unbifurcated ruling, being a full-blooded infringement-and-invalidity action running to 243 paragraphs. [read post]
